Evommune, Inc. Posts Updated Corporate Presentation (8‑K)

What Happened

• Evommune, Inc. (EVMN) announced under Regulation FD on September 15, 2026 that it posted an updated corporate presentation on the “Company Info” page of its investor website (https://ir.evommune.com/company-info/presentations). The presentation is furnished with the Current Report on Form 8-K as Exhibit 99.1.

Key Details

• Filing date: September 15, 2026 (Form 8-K, Item 7.01 Regulation FD Disclosure).
• Presentation furnished as Exhibit 99.1 to the 8-K; interactive cover page XBRL (Exhibit 104) also included.
• The company states its website content is not incorporated by reference into the 8-K and it has no obligation to update the attached presentation.
• Report signed by Luis Peña, President and Chief Executive Officer.

Why It Matters

• Posting an updated corporate presentation provides investors and analysts with the company’s current messaging and may include refreshed business, clinical or strategic information useful for evaluating Evommune.
• Because this is a Regulation FD disclosure, the company is publicly sharing material investor presentation materials to ensure broad access rather than selective disclosure.
• The 8-K itself does not report financial results, management changes, or new transactions—investors should review the attached Exhibit 99.1 presentation for any substantive updates.